# Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

> **NCT04004442** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oklahoma** · enrollment: 19 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** AVB-S6-500

## Key facts

- **NCT ID:** NCT04004442
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-17
- **Primary completion:** 2022-04-07
- **Final completion:** 2026-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004442, "Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04004442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*